Scancell Holdings

SCLP: 6.30 0.00 (0.00%) delayed: 18 Feb 2020, 16:57

Trade now
Bid Price 6.50 High Price 0.00
Ask Price 6.60 Low Price 0.00
Open Price 0.00 Spread 0.00%
Prev Close 6.55 Volume 0

Scancell Holdings Share Price

Historic - 6 months
>> Advanced Scancell Holdings Charts >>

Scancell Holdings Share Price Information

Name Scancell Holdings
Sector Biotechnology
ISIN GB00B63D3314
Activites Scancell Holdings plc is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms. Scancell's first ImmunoBody, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence. Scancell's ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site, and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells. Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that have the ability to destroy tumours with minimal toxicity. The Directors believe that the Moditope platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
Index n/a
Latest Share Price (p) 0.00 Net Gearing (%) -31.82
Market Capitalisation (£m) 33.27 Gross Gearing (%) 11.43
Shares in issue (m) 465.36 Debt Ratio 0.00
P/E Ratio -4.93 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.13
Dividend Yield (%) 0.00 Price to book value 3.56
Dividend Cover 0.00 ROCE (%) -71.92
Earning per share (p) -1.45 EPS Growth (%) -8.21
52-week high / low (p) 9.75 / 3.70 DPS Growth (%) n/a

Scancell Holdings Broker Views

Date Broker Recommendation Price Old Target Price New Target Price Notes
11 Jul Panmure Gordon Buy 6.55 68.00 68.00 Retains
20 Apr Panmure Gordon Buy 6.55 68.00 68.00 Retains
31 Jan Panmure Gordon Buy 6.55 68.00 68.00 Retains
26 Jan Panmure Gordon Buy 6.55 68.00 68.00 Retains
03 Jan Panmure Gordon Buy 6.55 68.00 68.00 Retains
>> More Scancell Holdings Broker Views >>

Scancell Holdings Director Deals

Date Director Type Volume / Price Trade Value
17 Dec 2019 Martin Diggle Buy 2,925,000 @ 5.20p £152,100.00
22 Oct 2013 Prof Lindy Durrant Sell 100,000 @ 30.00p £30,000.00
22 Oct 2013 Dr Richard Goodfellow Sell 100,000 @ 30.00p £30,000.00
12 Aug 2013 Peter Allen Buy 50,000 @ 33.00p £16,500.00
23 Jul 2013 David Evans Buy 30,000 @ 31.80p £9,540.00
>> More Scancell Holdings Director Deals >>

Scancell Holdings News

>> More Scancell Holdings News >>